(Q36723849)

15 August 2017

1 reference

title

Nesiritide: a reappraisal of efficacy and safety (English)

1 reference

15 August 2017

2

John R Teerlink

1 reference

15 August 2017

Sanjiv J Shah

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

8

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

361-369

1 reference

ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Evaluation and management of patients with acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Overview of randomized clinical trials in acute heart failure syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Nesiritide for the treatment of decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Nesiritide for the treatment of congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Effects of Intravenous Nesiritide on Human Coronary Vasomotor Regulation and Myocardial Oxygen Uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

B-type natriuretic peptide: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Nesiritide in acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Nesiritide: a new drug for the treatment of decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Relationship between heart failure treatment and development of worsening renal function among hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Renal impairment and outcomes in heart failure: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

The cardiorenal syndrome: lessons from the ADHERE database and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

Risk of death associated with nesiritide in patients with acutely decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.361

21 January 2018

Identifiers

DOI

10.1517/14656566.8.3.361

1 reference

15 August 2017

1 reference